C1RL-AS1: A Potential Drug Target and Biomarker (G283314)

Target Name: C1RL-AS1

NCBI ID: G283314

C1RL-AS1

Other Name(s): C1RL antisense RNA 1 | MATL2963

C1RL-AS1: A Potential Drug Target and Biomarker

Abstract

C1RL-AS1 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique structure and function have made it an attractive target for drug development, as well as a diagnostic tool for the diagnosis of certain diseases.

Introduction

C1RL-AS1 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique structure and function have made it an attractive target for drug development, as well as a diagnostic tool for the diagnosis of certain diseases.

Structure and Function

C1RL-AS1 is a small RNA molecule that consists of 19 amino acid residues. It has a unique structure, with a stem-loop and a 5'-end that is composed of a single polypeptide chain. The stem-loop region of C1RL- AS1 contains a unique feature, known as a double-stranded RNA structure, which is composed of two complementary strands that base-pair with each other. This structure is formed by the formation of a double-stranded RNA structure, which is then stable through The formation of a series of hydrogen bonds.

C1RL-AS1 functions as an RNA molecule that plays a role in the regulation of gene expression. It is expressed in various tissues and cells, including the brain, heart, and cancer cells. It has been shown to play a role in the regulation of cell proliferation, cell differentiation, and apoptosis.

Potential Drug Target

C1RL-AS1 is a potential drug target due to its unique structure and function. Its double-stranded RNA structure makes it a stable target for small molecules, such as drugs that can bind to specific RNA binding sites on the molecule. Additionally, its expression in various tissues and cells makes it a potential target for drugs that can affect gene expression in those cells.

One of the most promising aspects of C1RL-AS1 as a drug target is its role in cancer. Cancer is a disease that is characterized by the uncontrolled growth and spread of cells. C1RL-AS1 has been shown to play a role in the regulation of cell proliferation and apoptosis, which are important factors in the development and progression of cancer. Therefore, drugs that can target C1RL-AS1 and disrupt its function in these ways may be effective in treating cancer.

Biomarker

C1RL-AS1 has also been identified as a potential biomarker for various diseases, including cancer. Its unique structure and function make it a potential target for diagnostic tools that can detect and measure the expression of C1RL-AS1 in various tissues and cells. This could be useful for the diagnosis of diseases that are characterized by the uncontrolled growth and spread of cells, such as cancer.

Conclusion

C1RL-AS1 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique structure and function have made it an attractive target for drug development, as well as a diagnostic tool for the diagnosis of certain diseases. Further research is needed to fully understand the function of C1RL-AS1 and its potential as a drug and biomarker.

Protein Name: C1RL Antisense RNA 1

The "C1RL-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C1RL-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets